Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulforaphane for inflammation in virally suppressed HIV
NCT05224492Phase 4Unknown
- Sponsor
- Sunshine Specialty Health Care
- Start
- Feb 2022
- Primary completion
- Jul 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Sulforaphane Group with Placebo Group (2 arms). Primary endpoints: Lipid Profile at 4 months and Inflammatory Markers at 4 months. Status: unknown.
02
Drugs
sulforaphane
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05224492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05224492.